目的探讨经皮椎体成形术(PVP)中分期注射法对于脊柱病变治疗的安全性及有效性。方法回顾性分析228例患者,443节手术椎体,根据手术方法的不同将患者分为两组:A组(采用分期注射法)和B组(无分期注射法),所有患者随访12个月,随访过程中采用...目的探讨经皮椎体成形术(PVP)中分期注射法对于脊柱病变治疗的安全性及有效性。方法回顾性分析228例患者,443节手术椎体,根据手术方法的不同将患者分为两组:A组(采用分期注射法)和B组(无分期注射法),所有患者随访12个月,随访过程中采用视觉模拟评分(VAS)及Oswestry功能障碍指数(ODI)评价临床疗效,采用统计学方法对随访数据进行统计学分析。结果所有患者顺利完成手术,A组患者每节椎体骨水泥注入量平均(4.75±0.85) m L,B组患者骨水泥注入量平均(4.23±1.16) m L,A组患者81节椎体(23.9%)发生骨水泥渗漏,B组患者36节椎体(34.6%)发生骨水泥渗漏,骨水泥渗漏周围组织,未引起明显不适。对随访数据进行统计学分析显示,A组术后1 d和1个月VAS及ODI评分优于B组,差异有统计学意义,但是A组与B组术后6和12个月VAS及ODI评分差异无统计学意义。结论 PVP是治疗椎体病变安全有效的方法,为达到解剖学上的修复,从而最大程度恢复脊柱稳定性,缓解症状,在PVP中采用分期注射法是一种安全及有效的手术方法。展开更多
OBJECTIVE： To evaluate the clinical efficacy of safflower yellow injection combined with conventional therapy in treating unstable angina pectoris.METHODS： We searched online databases： Chinese journal full-text da...OBJECTIVE： To evaluate the clinical efficacy of safflower yellow injection combined with conventional therapy in treating unstable angina pectoris.METHODS： We searched online databases： Chinese journal full-text database, China National Knowledge Infrastructure, Wanfang database, Chinese journal full-text database, Pubmed, ScienceDirect,Embase, and the Cochrane Library with manual-screening of relevant literature. Eligible randomized controlled trials（RCT） on angina pectoris were included. We conducted meta-analysis using the RevMan 5.1 software from The Cochrane Collaboration. We treated the relief rate of angina symptoms and electrocardiograph（ECG） as evaluation.RESULTS： Seven articles, including in 1134 patients, were enrolled after the evaluation. Therewas no significant heterogeneity among the studies（χ2=1.08, df=6, P=0.98, I2=0%）. The safflower yellow injection with conventional therapy has a higher effective rate than the control group in relieving the symptoms of angina pectoris [odds ratio（OR）=2.95, 95%（CI）（1.81, 4.81）] and improving ischemic ECG [OR=2.85, 95% CI（1.67, 4.86）]. The difference was statistically significant in the ＂80 mg dosage＂ and ＂100 mg dosage＂ subgroups（P0.05） for improving clinical symptoms and ECG. The funnel graphic was nearly symmetrical. Sensitivity analysis suggested that the results were stable.CONCLUSION： Safflower yellow injection as an adjunct therapy with conventional drugs shows advantages in easing the clinical symptoms of unstable angina and improving ECG over basic therapy alone. However, the conclusions should be interpreted with care until more high-quality RCTs are reported.展开更多
文摘目的探讨经皮椎体成形术(PVP)中分期注射法对于脊柱病变治疗的安全性及有效性。方法回顾性分析228例患者,443节手术椎体,根据手术方法的不同将患者分为两组:A组(采用分期注射法)和B组(无分期注射法),所有患者随访12个月,随访过程中采用视觉模拟评分(VAS)及Oswestry功能障碍指数(ODI)评价临床疗效,采用统计学方法对随访数据进行统计学分析。结果所有患者顺利完成手术,A组患者每节椎体骨水泥注入量平均(4.75±0.85) m L,B组患者骨水泥注入量平均(4.23±1.16) m L,A组患者81节椎体(23.9%)发生骨水泥渗漏,B组患者36节椎体(34.6%)发生骨水泥渗漏,骨水泥渗漏周围组织,未引起明显不适。对随访数据进行统计学分析显示,A组术后1 d和1个月VAS及ODI评分优于B组,差异有统计学意义,但是A组与B组术后6和12个月VAS及ODI评分差异无统计学意义。结论 PVP是治疗椎体病变安全有效的方法,为达到解剖学上的修复,从而最大程度恢复脊柱稳定性,缓解症状,在PVP中采用分期注射法是一种安全及有效的手术方法。
基金Supported by Liaoning Province Science and Technology Plan Projects,Traditional Chinese Medicine Efficacy Evaluation Key Technology Research(No.2010225034)and(No.2010ZX09401-304)
文摘OBJECTIVE： To evaluate the clinical efficacy of safflower yellow injection combined with conventional therapy in treating unstable angina pectoris.METHODS： We searched online databases： Chinese journal full-text database, China National Knowledge Infrastructure, Wanfang database, Chinese journal full-text database, Pubmed, ScienceDirect,Embase, and the Cochrane Library with manual-screening of relevant literature. Eligible randomized controlled trials（RCT） on angina pectoris were included. We conducted meta-analysis using the RevMan 5.1 software from The Cochrane Collaboration. We treated the relief rate of angina symptoms and electrocardiograph（ECG） as evaluation.RESULTS： Seven articles, including in 1134 patients, were enrolled after the evaluation. Therewas no significant heterogeneity among the studies（χ2=1.08, df=6, P=0.98, I2=0%）. The safflower yellow injection with conventional therapy has a higher effective rate than the control group in relieving the symptoms of angina pectoris [odds ratio（OR）=2.95, 95%（CI）（1.81, 4.81）] and improving ischemic ECG [OR=2.85, 95% CI（1.67, 4.86）]. The difference was statistically significant in the ＂80 mg dosage＂ and ＂100 mg dosage＂ subgroups（P0.05） for improving clinical symptoms and ECG. The funnel graphic was nearly symmetrical. Sensitivity analysis suggested that the results were stable.CONCLUSION： Safflower yellow injection as an adjunct therapy with conventional drugs shows advantages in easing the clinical symptoms of unstable angina and improving ECG over basic therapy alone. However, the conclusions should be interpreted with care until more high-quality RCTs are reported.
